Long-term follow-up of study participants from prophylactic HIV vaccine clinical trials in Africa

References

• Peters BS, Jaoko W, Vardas E, Panayotakopoulos G, Fast P, Schmidt C, Gilmour J, Bogoshi M, Omosa-Manyonyi G, Dally L, et al. Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity. Vaccine 2007; 25:2120 - 7; http://dx.doi.org/10.1016/j.vaccine.2006.11.016; PMID: 17250931
   PubMed Web of Science ®Google Scholar
• Jaoko W, Nakwagala FN, Anzala O, Manyonyi GO, Birungi J, Nanvubya A, Bashir F, Bhatt K, Ogutu H, Wakasiaka S, et al. Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa. Vaccine 2008; 26:2788 - 95; http://dx.doi.org/10.1016/j.vaccine.2008.02.071; PMID: 18440674
   PubMed Web of Science ®Google Scholar
• Vardas E, Kaleebu P, Bekker LG, Hoosen A, Chomba E, Johnson PR, Anklesaria P, Birungi J, Barin B, Boaz M, et al. A phase 2 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 vaccine based on adeno-associated virus. AIDS Res Hum Retroviruses 2010; 26:933 - 42; http://dx.doi.org/10.1089/aid.2009.0242; PMID: 20666584
   PubMed Web of Science ®Google Scholar
• Jaoko W, Karita E, Kayitenkore K, Omosa-Manyonyi G, Allen S, Than S, Adams EM, Graham BS, Koup RA, Bailer RT, et al. Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa. PLoS One 2010; 5:e12873; http://dx.doi.org/10.1371/journal.pone.0012873; PMID: 20877623
   PubMed Web of Science ®Google Scholar
• Gilbert PB, Chiu Y-L, Allen M, Lawrence DN, Chapdu C, Israel H, Holman D, Keefer MC, Wolff M, Frey SE, NIAID HIV Vaccine Trials Network. Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials. Vaccine 2003; 21:2933 - 47; http://dx.doi.org/10.1016/S0264-410X(03)00158-0; PMID: 12798637
   PubMed Web of Science ®Google Scholar
• Schmidt C, Smith C, Barin B, Bakhtyari A, Bart PA, Bekker LG, Chomba E, Clumeck N, Ho D, Hoosen A, et al. Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events. Hum Vaccin Immunother 2012; 8:630 - 8; http://dx.doi.org/10.4161/hv.19454; PMID: 22634443
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Cardiac adverse events following smallpox vaccination--United States, 2003. MMWR Morb Mortal Wkly Rep 2003; 52:248 - 50; PMID: 12680519
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention (CDC). Update: cardiac-related events during the civilian smallpox vaccination program--United States, 2003. MMWR Morb Mortal Wkly Rep 2003; 52:492 - 6; PMID: 12809110
   PubMedGoogle Scholar
• Vasan S, Schlesinger SJ, Chen Z, Hurley A, Lombardo A, Than S, Adesanya P, Bunce C, Boaz M, Boyle R, et al. Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B’/C candidate vaccine. PLoS One 2010; 5:e8816; http://dx.doi.org/10.1371/journal.pone.0008816; PMID: 20111599
   PubMed Web of Science ®Google Scholar
• Ramanathan VD, Kumar M, Mahalingam J, Sathyamoorthy P, Narayanan PR, Solomon S, Panicali D, Chakrabarty S, Cox J, Sayeed E, et al. A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers. AIDS Res Hum Retroviruses 2009; 25:1107 - 16; http://dx.doi.org/10.1089/aid.2009.0096; PMID: 19943789
   PubMed Web of Science ®Google Scholar
• Elizaga ML, Vasan S, Marovich MA, Sato AH, Lawrence DN, Chaitman BR, Frey SE, Keefer MC, MVA Cardiac Safety Working Group. Prospective surveillance for cardiac adverse events in healthy adults receiving modified vaccinia Ankara vaccines: a systematic review. PLoS One 2013; 8:e54407; http://dx.doi.org/10.1371/journal.pone.0054407; PMID: 23349878
   PubMed Web of Science ®Google Scholar
• Poster # 164668: Karita E, Kayitesi K, Bayingama R, Sebahungu F, Bizimana J, Grabowski K, et al. Use of HIV rapid test for assessment of persistence of vaccine-induced antibodies among HIV vaccine recipients. AIDS Vaccine 2009, Paris, October 2009.
   Google Scholar
• Van Braeckel E, Koutsoukos M, Bourguignon P, Clement F, McNally L, Leroux-Roels G. Vaccine-induced HIV seropositivity: a problem on the rise. J Clin Virol 2011; 50:334 - 7; http://dx.doi.org/10.1016/j.jcv.2011.01.003; PMID: 21300566
   PubMed Web of Science ®Google Scholar
• Cooper CJ, Metch B, Dragavon J, Coombs RW, Baden LR, NIAID HIV Vaccine Trials Network (HVTN) Vaccine-Induced Seropositivity (VISP) Task Force. Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients. JAMA 2010; 304:275 - 83; http://dx.doi.org/10.1001/jama.2010.926; PMID: 20639561
   PubMed Web of Science ®Google Scholar
• DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. . www.rsc-tech.com
   Google Scholar
• Boaz MJ, Hayes P, Tarragona T, Seamons L, Cooper A, Birungi J, Kitandwe P, Semaganda A, Kaleebu P, Stevens G, et al. Concordant proficiency in measurement of T-cell immunity in human immunodeficiency virus vaccine clinical trials by peripheral blood mononuclear cell and enzyme-linked immunospot assays in laboratories from three continents. Clin Vaccine Immunol 2009; 16:147 - 55; http://dx.doi.org/10.1128/CVI.00326-08; PMID: 19091991
   PubMed Web of Science ®Google Scholar
• Keefer MC, Gilmour J, Hayes P, Gill D, Kopycinski J, Cheeseman H, Cashin-Cox M, Naarding M, Clark L, Fernandez N, et al. A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One 2012; 7:e41936; http://dx.doi.org/10.1371/journal.pone.0041936; PMID: 22870265
   PubMed Web of Science ®Google Scholar